A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat or Placebo When co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia.
Latest Information Update: 11 Apr 2022
Price :
$35 *
At a glance
- Drugs Lapaquistat (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 07 Apr 2022 This trial has been completed in Spain (Global end date: 06-03-2007), according to European Clinical Trials Database record
- 06 Apr 2022 This trial has been completed in Norway (Global end date 06-03-2007), according to European Clinical Trials Database record.
- 24 Mar 2009 Actual patient number (649) added as reported by ClinicalTrials.gov.